Work

Omalizumab in Patients with Severe Asthma and Persistent Sputum Eosinophilia

Year: 2019

Type: article

Abstract: Omalizumab (anti-IgE monoclonal antibody) is the first approved biologic for treating allergic asthma. It’s steroid-sparing effect by monitoring steroid-responsive biomarkers such as sputum eosinophils has not been investigated in randomized clinical trials.

Source: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2018.12.984

Authors: Manali Mukherjee, Melanie Kjarsgaard, Katherine Radford, Chynna Huang, Richard Leigh, Del Dorscheid, Catherine Lemiere, Louis-Philippe Boulet, Susan Waserman, James G. Martin, Parameswaran K. Nair

Institutions: McMaster University, University of Calgary, University of British Columbia, Hôpital du Sacré-Cœur de Montréal, Université Laval, McGill University Health Centre, McGill University

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Teva Pharmaceutical Industries, Canadian Allergy, Asthma and Immunology Foundation, Université de Montréal, Canadian Institutes of Health Research

OpenAlex ID: W2913449079

FWCI: 0.343

Cites:

Cited by: 4

Related to: 10